Cancer Clinical Trial Participation May Not Actually Improve Survival, Study Says, MedPage Today May 22, 2024
These comparisons involved hematologic (21%), breast (16%), lung (14%), central nervous system (7%), prostate (7%), and pancreatic cancers (5%), as well as melanoma (6%), with bladder, cervical, colorectal, esophageal, gastric, head and neck, kidney, ovarian, and solid mix tumors making up the remaining
These comparisons involved hematologic (21%), breast (16%), lung (14%), central nervous system (7%), prostate (7%), and pancreatic cancers (5%), as well as melanoma (6%), with bladder, cervical, colorectal, esophageal, gastric, head and neck, kidney, ovarian, and solid mix tumors making up the remaining